Gonzalez Stevan A
Division of Hepatology, Annette C. and Harold C. Simmons Transplant Institute, Baylor All Saints Medical Center at Fort Worth and Baylor University Medical Center at Dallas, Fort Worth, TX, USA.
Hepatobiliary Surg Nutr. 2014 Dec;3(6):410-4. doi: 10.3978/j.issn.2304-3881.2014.07.06.
Hepatocellular carcinoma (HCC) remains a major cause of mortality in patients with chronic liver disease worldwide. Early detection of HCC is critical to providing effective treatment and can have a significant impact on survival. In addition, effective surveillance following hepatic resection or locoregional ablative therapy can identify early recurrence and optimize long-term outcomes. Currently available serum tumor markers, including alpha-fetoprotein (AFP), are characterized by low sensitivity in the detection of HCC. Advances in genomic, proteomic, metabolomic, and glycomic profiling may provide a means to identify unique molecular signatures and characterization of complex processes associated with HCC incidence and recurrence. The development of highly sensitive and specific serum biomarkers for HCC may greatly enhance early detection rates, risk assessment in treatment candidates, and identification of potential new targets for anticancer therapy.
肝细胞癌（HCC）仍然是全球慢性肝病患者死亡的主要原因。早期发现HCC对于提供有效治疗至关重要，并且对生存率有重大影响。此外，肝切除或局部消融治疗后的有效监测可以识别早期复发并优化长期预后。目前可用的血清肿瘤标志物，包括甲胎蛋白（AFP），在检测HCC时具有低敏感性的特点。基因组、蛋白质组、代谢组和糖组分析的进展可能提供一种手段，以识别与HCC发生和复发相关的独特分子特征以及复杂过程的特征。开发用于HCC的高度敏感和特异的血清生物标志物可能会大大提高早期检测率、治疗候选者的风险评估以及识别抗癌治疗的潜在新靶点。
